Literature DB >> 2461824

Quantity of anti-leucoprotease relative to alpha 1-proteinase inhibitor in peripheral airspaces of the human lung.

J A Kramps1, C Franken, J H Dijkman.   

Abstract

1. Peripheral airspaces were selectively lavaged using balloon-tipped catheters of 2 mm diameter. 2. Molar anti-leucoprotease/alpha 1-proteinase inhibitor ratios as determined in these lavage fluids by enzyme immunoassays ranged from 0.02 to 0.14 (mean 0.08). 3. These data indicate that peripheral airspaces contain minor amounts of anti-leucoprotease relative to alpha 1-proteinase inhibitor. This observation does not necessarily mean that anti-leucoprotease is of minor importance in protecting the lung interstitium.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2461824     DOI: 10.1042/cs0750351

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  12 in total

1.  Plasma leucocyte elastase concentrations in smokers.

Authors:  C R Hind; H Joyce; G A Tennent; M B Pepys; N B Pride
Journal:  J Clin Pathol       Date:  1991-03       Impact factor: 3.411

Review 2.  Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor.

Authors:  Stergios Doumas; Alexandros Kolokotronis; Panagiotis Stefanopoulos
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

3.  Expression of the secretory leukoprotease inhibitor gene in epithelial cells.

Authors:  T Abe; N Kobayashi; K Yoshimura; B C Trapnell; H Kim; R C Hubbard; M T Brewer; R C Thompson; R G Crystal
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

4.  Serum Clara cell protein levels in lung cancer patients: an assessment of preoperative values and postoperative changes.

Authors:  H Nomori; H Horio; R Kobayashi; S Morinaga
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

5.  Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients.

Authors:  A A Baqui; T F Meiller; W A Falkler
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

6.  Antibacterial activity of antileukoprotease.

Authors:  P S Hiemstra; R J Maassen; J Stolk; R Heinzel-Wieland; G J Steffens; J H Dijkman
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

7.  Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor.

Authors:  C Vogelmeier; R C Hubbard; G A Fells; H P Schnebli; R C Thompson; H Fritz; R G Crystal
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

8.  Protein 1 and Clara cell 10-kDa protein distribution in normal and neoplastic tissues with emphasis on the respiratory system.

Authors:  H Nomori; S Morinaga; R Kobayashi; C Torikata
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

9.  Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor.

Authors:  N G McElvaney; H Nakamura; P Birrer; C A Hébert; W L Wong; M Alphonso; J B Baker; M A Catalano; R G Crystal
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

10.  Alpha 1-proteinase inhibitor and mucus proteinase inhibitor in human lung emphysema.

Authors:  G Trefz; J Schliesser; B Heck; V Schulz; W Ebert
Journal:  Clin Investig       Date:  1992 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.